TG Therapeutics, Inc. $TGTX Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 116.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 153,132 shares of the biopharmaceutical company’s stock after purchasing an additional 82,253 shares during the quarter. Intech Investment Management LLC’s holdings in TG Therapeutics were worth $4,565,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Congress Asset Management Co. acquired a new position in shares of TG Therapeutics in the 4th quarter valued at $57,307,000. Nordea Investment Management AB purchased a new position in shares of TG Therapeutics in the 4th quarter valued at $2,356,000. Penn Capital Management Company LLC raised its stake in shares of TG Therapeutics by 17.6% in the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock valued at $18,877,000 after acquiring an additional 77,895 shares during the period. Public Sector Pension Investment Board raised its stake in shares of TG Therapeutics by 14.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock valued at $19,120,000 after acquiring an additional 66,911 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of TG Therapeutics by 56.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock valued at $8,234,000 after acquiring an additional 81,907 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TGTX. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of TG Therapeutics in a research note on Wednesday, May 27th. Zacks Research downgraded shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. cut their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $37.94 on Monday. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $44.65. The company has a market capitalization of $5.81 billion, a price-to-earnings ratio of 13.27 and a beta of 1.68. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The firm’s fifty day moving average price is $36.21 and its 200 day moving average price is $32.32.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The firm had revenue of $204.92 million for the quarter, compared to analysts’ expectations of $200.33 million. During the same period last year, the firm earned $0.03 EPS. The business’s quarterly revenue was up 69.5% on a year-over-year basis. On average, research analysts forecast that TG Therapeutics, Inc. will post 1.31 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.